In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up Previews, April 2013

Executive Summary

This Month's Profile Group: Using Quantified-Self Data To Enhance Fertility And Pregnancy, features profiles of Fertility Focus, Ovuline, and Unifvy. Plus these Start-Ups Across Health Care: Actium Biosystems, MacuLogix, Novan, and Presage Biosciences.

You may also be interested in...



Actium Biosystems LCC

The Actium Cancer Treatment System from Actium Biosystems LLC is designed to improve bladder cancer treatment by selectively heating chemotherapeutic agents within the body to drive them more deeply into tumors. Studies confirm that as much as four times the amount of drug reaches the cancer tumor with the addition of hyperthermia, compared with the standard of care for chemotherapy that does not use any heat and thus treats at the normal body temperature.

MacuLogix Inc.

The AdaptDx from MacuLogix Inc. has the potential to be the first practical diagnostic instrument for early detection of AMD. Akin to routine peripheral vision testing for glaucoma, the noninvasive desktop device measures impaired dark adaptation (the speed with which vision is recovered when moving from a brightly lit environment to darkness), an early-stage marker of AMD development.

Univfy Inc.

Univfy Inc. has developed evidence-based, personalized prediction models of in vitro fertilization treatment success for fertility patients and their health care providers, as a support tool to help increase the success of IVF, decrease dropout rates, and better assess the risks of the procedure.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV004028

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel